The FDA drugs database lists a supplemental approval dated 18 August 2026 for TYZAVAN, vancomycin hydrochloride, under Hikma's new drug application NDA 211962.
The record does not state what the supplement covers. Supplements can change labelling, manufacturing, packaging or presentation, and most do not alter how a drug is used clinically. Nothing in the record indicates a new indication or a safety finding.
TYZAVAN is a US product. Its status with CDSCO is not known. For prescribers, vancomycin dosing and monitoring practice is unchanged by this action.
- No change to vancomycin indications or dosing follows from this record
- Check the updated label on the FDA database if you use this product
- Continue AUC-guided or trough-guided monitoring per local protocol
Why it matters
Regulatory listings for antibiotics are worth scanning, but this one carries no clinical signal on current information.
Don't overread it
A licence supplement is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free